Hypertrophic intraventricular flow obstruction after very-low-dose dexamethasone (Minidex) in preterm infants: case presentation and review of the literature.

Abstract

The use of dexamethasone in preterm infants developing bronchopulmonary dysplasia has been proven to be effective. Hypertrophic cardiomyopathy is a frequently reported, although transient, side effect of high-dose dexamethasone administration. The recent introduction of very low dexamethasone dose, called 'Minidex', promised equal effectiveness compared to high-dose dexamethasone without relevant side effects. Our study presents two patients developing hypertrophic cardiomyopathy with intraventricular cardiac obstruction after administration of 'Minidex'. Marked cardiac side effects may occur even during very-low-dose dexamethasone treatment in preterm neonates. Betablocker and discontinuation of dexamethasone seem to allow spontaneous reversal of myocardial hypertrophy and obstruction. After all, systematic surveys of the incidence of cardiac complications in a larger population of preterm infants treated with very low doses of dexamethasone are needed.

• Authors: C Paech, N Wolf, U H Thome, M Knüpfer
• Journal: Journal of perinatology : official journal of the California Perinatal Association (J Perinatol) Vol. 34 Issue 3 Pg. 244-6 (Mar 2014) ISSN: 1476-5543 [Electronic] United States
• PMID: 24573211 (Publication Type: Case Reports, Journal Article, Review)

Chemical References

• Dexamethasone

Topics

• Bronchopulmonary Dysplasia (prevention & control)
• Cardiomegaly (chemically induced)
• Dexamethasone (administration & dosage, adverse effects)
• Echocardiography
• Humans
• Infant, Newborn
• Infant, Premature
• Infant, Premature, Diseases (chemically induced, diagnostic imaging)
• Ventricular Outflow Obstruction (chemically induced, diagnostic imaging)